Oric Pharmaceuticals, Inc. (ORIC)
ORIC Pharmaceuticals develops cancer drug candidates in South San Francisco, led by rinzimetostat for prostate cancer and enozertinib for lung cancer. It last closed at $8.00 on Nov 17, up 6.38% on the day. The average 12-month price target from 5 analysts is $22.00 (+175.0% from the last close), with a high of $26.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in ORIC, 0% of them bullish and 100% bearish.
Key Stats
Last 12 monthsNot reported for this period.
From ORIC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on ORIC in the past 90 days. The average target is $22.00, with a high of $26.00 and a low of $14.00, compared with the last close of $8.00.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 17 | BTIG | Reiterated | Buy | $26 |
| Oct 28 | BTIG | Reiterated | Buy | $26 |
| Oct 27 | Wedbush | Maintained | Buy | $14 |
| Oct 26 | Stifel | Maintained | Buy | $18 |
| Oct 14 | JP Morgan | Maintained | Buy | $26 |
Technical Analysis
The stock is 19% below its 20 day and 42% below its 50 day average. It is 37% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 35), near oversold. The nearest support is the Pivot at $7.86, and the nearest resistance the Pivot R1 at $8.15.
| RSI (14) | 34.91 | Weak, oversold below 30 | Neutral |
| MACD | -1.04 | Below its signal line | Bearish |
| Stochastic | 6.9 | Near the bottom of its range | Oversold |
| ADX (14) | 29.0 | Trending down | |
| Williams %R | -80.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -93.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −16.6% | Change over 10 sessions | Bearish |
| ATR (14) | $0.77 | Typical daily range, 9.7% of price |
| RSI (14) | 37.50 | Weak, oversold below 30 | Neutral |
| MACD | -0.45 | Below its signal line | Bearish |
| Stochastic | 5.2 | Near the bottom of its range | Oversold |
| ADX (14) | 19.8 | No clear trend | |
| Williams %R | -93.0 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -192.8 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −33.5% | Change over 10 sessions | Bearish |
| ATR (14) | $1.75 | Typical daily range, 21.9% of price |
What happened before
See how ORIC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ORIC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in ORIC in the last 90 days.
ORIC Institutional Ownership
Full report →- ▲116 buying vs 75 selling
- ▼Held by funds -4.8 pts
- ▲Funds holding +22
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 203 | 181 | +12.2% |
| In funds' top 10 | 9 | 8 | +12.5% |
| Held by funds | 114.1% | 118.9% | −4.8 pts |
| New / increased | 42 / 74 | 29 / 82 | +4.5% |
| Reduced / sold out | 56 / 19 | 42 / 30 | +4.2% |
| Put/call ratio | 0.04 | 0.11 | −63.4% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ORIC is in one of them and how their past ORIC trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ORIC in an article yet. Here's the latest on the wider market.
About Oric Pharmaceuticals
ORIC Pharmaceuticals is a biopharmaceutical company based in South San Francisco, California, that develops cancer treatments designed to counter drug resistance. Its two lead candidates are rinzimetostat, which is being studied in advanced prostate cancer, and enozertinib, which is being studied in lung cancer with certain EGFR gene mutations. Neither candidate has been approved for sale yet.
- Headquarters
- South San Francisco, CA

